Psoriatic arthritis flare; Redness/pain/swelling at site of first moderna covid vaccine; Redness/pain/swelling at site of first moderna covid vaccine; Redness/pain/swelling at site of first moderna covid vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PSORIATIC ARTHROPATHY (Psoriatic arthritis flare) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    There was no reported medical history.  Concurrent medical conditions included Psoriatic arthritis.   On 01-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. In January 2021, the patient experienced VACCINATION SITE JOINT ERYTHEMA (Redness/pain/swelling at site of first moderna covid vaccine), VACCINATION SITE PAIN (Redness/pain/swelling at site of first moderna covid vaccine) and VACCINATION SITE SWELLING (Redness/pain/swelling at site of first moderna covid vaccine). On an unknown date, the patient experienced PSORIATIC ARTHROPATHY (Psoriatic arthritis flare) (seriousness criterion medically significant). The patient was treated with METHYLPREDNISOLONE (MEDROL [METHYLPREDNISOLONE]) at an unspecified dose and frequency. At the time of the report, PSORIATIC ARTHROPATHY (Psoriatic arthritis flare) was resolving and VACCINATION SITE JOINT ERYTHEMA (Redness/pain/swelling at site of first moderna covid vaccine), VACCINATION SITE PAIN (Redness/pain/swelling at site of first moderna covid vaccine) and VACCINATION SITE SWELLING (Redness/pain/swelling at site of first moderna covid vaccine) outcome was unknown.            It was unknown if patient was enrolled in COVID-19-Vaccine Trial. The reporter's causality for the event(s) of Injection site pain after first COVID Vaccine, Injection site redness after first COVID Vaccine, Psoriatic arthritis flare with Humira Solution for Injection was not provided.  The patient received second dose of Moderna vaccine on 01-Feb-2021.  The patient received Janssen COVID-19 vaccine on 01-Jan-2022.  Company Comment: This is a spontaneous case concerning a 43-year-old female patient with underlying disease of Psoriatic arthritis, who experienced the unexpected, serious (medically significant) event of Psoriatic arthropathy (Psoriatic arthritis flare), on unknown date after receiving the first dose of mRNA-1273 vaccine. Relevant diagnostic tests were not provided in the case. The patient was treated with methylprednisolone. The event was resolving at the time of the report. Underlying disease of Psoriatic arthritis remains a risk factor for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to MOD-2022-682835 (Patient Link).   Reporter did not allow further contact; Sender's Comments: This is a spontaneous case concerning a 43-year-old female patient with underlying disease of Psoriatic arthritis, who experienced the unexpected, serious (medically significant) event of Psoriatic arthropathy (Psoriatic arthritis flare), on unknown date after receiving the first dose of mRNA-1273 vaccine. Relevant diagnostic tests were not provided in the case. The patient was treated with methylprednisolone. The event was resolving at the time of the report. Underlying disease of Psoriatic arthritis remains a risk factor for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.